Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy

Small cell lung cancers (SCLCs) rapidly resist cytotoxic chemotherapy and immune checkpoint inhibitor (ICI) treatments. New, non-cross-resistant therapies are thus needed. SCLC cells are committed into neuroendocrine lineage then maturation arrested. Implicating DNA methyltransferase 1 (DNMT1) in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Biswas, Sudipta, Kang, Kai, Ng, Kwok Peng, Radivoyevitch, Tomas, Schalper, Kurt, Zhang, Hua, Lindner, Daniel J., Thomas, Anish, MacPherson, David, Gastman, Brian, Schrump, David S., Kwok-Kin, Wong, Velcheti, Vamsidhar, Saunthararajah, Yogen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528072/
https://www.ncbi.nlm.nih.gov/pubmed/37597186
http://dx.doi.org/10.1016/j.celrep.2023.113016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528072/
https://www.ncbi.nlm.nih.gov/pubmed/37597186
http://dx.doi.org/10.1016/j.celrep.2023.113016

Ejemplares similares